호주의 급여의약품 청구데이터의 활용에 대한 고찰: Atorvastatin의 사용량과 청구액 분석 사례를 중심으로
Application of Australian Pharmaceutical Benefits Scheme data to the drug utilization studies: A case analysis on atorvastatin
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: The Australian Pharmaceutical Benefits Scheme (PBS) is a national drug subsidy program. Given the similarity and comprehensiveness of the Australian PBS and the Korean National Health Insurance (NHI) data, these data are increasingly used for pharmacoepidemiological investigations, as well as international comparative studies. This study aims to introduce the various sources of publicly available PBS data and provide a practical guide to researchers conducting drug utilization studies. Methods: We searched literature and websites to detail and compare the collection, structure, components, and characteristics of each PBS data format. We identified different characteristics of the PBS data from the Korean NHI claims data which are mainly owing to their unique co-payment policies and data collection processes. In addition, the utilization and expenditure of atorvastatin, a widely used treatment for hyperlipidemia, were analyzed using two different sources of PBS data and the different results were interpreted. Results: There exist differences in when data were collected or non-subsidized uses of medicine were included among sources of PBS data. Additionally, two countries have different cost sharing methods inmedicine subsidy scheme; co-payment in Australia and co-insurance in Korea. Therefore, it should be noted that prescriptions under co-payment are not included in some data sources in Australia. Conclusion: Despite several analytical challenges, open access and easy data management are the strengths of the PBS data sources. A detailed knowledge of the PBS data can ensure robust methodology and interpretation of pharmacoepidemiological investigations or international comparative studies.
Abstract
Objective: The Australian Pharmaceutical Benefits Scheme (PBS) is a national drug subsidy program. Given the similarity and comprehensiveness of the Australian PBS and the Korean National Health Insurance (NHI) data, these data are increasingly used for pharmacoepidemiological investigations, as well as international comparative studies. This study aims to introduce the various sources of publicly available PBS data and provide a practical guide to researchers conducting drug utilization studies. Methods: We searched literature and websites to detail and compare the collection, structure, components, and characteristics of each PBS data format. We identified different characteristics of the PBS data from the Korean NHI claims data which are mainly owing to their unique co-payment policies and data collection processes. In addition, the utilization and expenditure of atorvastatin, a widely used treatment for hyperlipidemia, were analyzed using two different sources of PBS data and the different results were interpreted. Results: There exist differences in when data were collected or non-subsidized uses of medicine were included among sources of PBS data. Additionally, two countries have different cost sharing methods inmedicine subsidy scheme; co-payment in Australia and co-insurance in Korea. Therefore, it should be noted that prescriptions under co-payment are not included in some data sources in Australia. Conclusion: Despite several analytical challenges, open access and easy data management are the strengths of the PBS data sources. A detailed knowledge of the PBS data can ensure robust methodology and interpretation of pharmacoepidemiological investigations or international comparative studies.
참고문헌 (26)
- "What is the PBS?"[URL]
- Avorn J, "In defense of pharmacoepidemiology-embracing the yin and yang of drug research", N Engl J Med, 357(22), pp.2219~2221 (2007)
- Chen YC, "Academic impact of a public electronic health database : bibliometric analysis of studies using the general practice research database", PloS One, 6(6), pp.e21404~ (2011)
- Pearson SA, "Studies using Australia's Pharmaceutical Benefits Scheme data for pharmacoepidemiological research: a systematic review of the published literature (1987–2013)", Pharmacoepidemiol Drug Saf, 24(5), pp.447~455 (2013)
- Wettermark B, "The Nordic prescription databases as a resource for pharmacoepidemiological research-a literature review", Pharmacoepidemiol Drug Saf, 22(7), pp.691~699 (2013)
- Henry D, "Access to routinely collected data for population health research : experiences in Canada and Australia", Aust N Z J Public Health, 42(5), pp.430~433 (2018)
- Leonard CE, "The quality of Medicaid and Medicare data obtained from CMS and its contractors : implications for pharmacoepidemiology", BMC Health Serv Res, 17(1), pp.304~ (2017)
- "Statistics on national health insurance expenditure 2018"[URL]
- "Statistics on food and drug 2018"[URL]
- 배은영, "한국, 호주, 캐나다의 의약품 급여평가결과 비교", 보건경제와 정책연구, 17(4), pp.1~21 (2011), 한국보건경제정책학회
- 정승연, "주요 외국의 희귀의약품과 항암제 별도 기금 제도 고찰 및 시사점", 약 학 회 지, 61(2), pp.100~108 (2017), 대한약학회
- 이영실, "주요 외국의 의약품 위험분담제도에 대한 고찰: 계약현황과 사후관리방안을 중심으로", 보건의료기술평가, 5(1), pp.13~21 (2017), 한국보건의료기술평가학회[DOI]
- 이혜재, "건강보험 약품비 구성 분석을 통한 지출효율화 방안 연구", 보건행정학회지, 28(4), pp.360~368 (2018), 한국보건행정학회
- "PBS expenditure and prescriptions"[URL]
- Roughead EE, "Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price", WHO South East Asia J Public Health, 7(2), pp.99~106 (2018)
- "Australian statistics on medicines"[URL]
- "Information on the australian statistics on medicines"[URL]
- "Pharmaceutical benefits schedule item reports"[URL]
- "National Health Amendment (Pharmaceutical Benefits Scheme) act 2010"[URL]
- "Pharmaceutical benefits scheme collection of under co-payment data"[URL]
- "Report on the collection of under co-payment data 2017-18"[URL]
- "Guidelines for ATC classification and DDD assignment 2019"[URL]
- "PBS and RPBS Section 85 date of supply data"[URL]
- Mellish L, "The Australian pharmaceutical benefits scheme data collection : a practical guide for researchers", BMC Res Notes, 8(1), pp.634~ (2015)
- Seaman KL, "Impact of consumer copayments for subsidised medicines on health services use and outcomes : a protocol using linked administrative data from Western Australia", BMJ open, 7(6), pp.e013691~ (2017)
- "Statistics on medicines"[URL]